BILLERICA, Mass.--(BUSINESS WIRE)--
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced it will host an Investor Day on November 16, 2016, in Boston, Massachusetts. The presentation will begin at 10:30 a.m. (Eastern Time) followed by a question and answer session, and is expected to end at 2:00 p.m., with product exhibits to follow. The day will end at 3:00 p.m. The presentation will be webcast live and may be accessed via Insulet’s website at http://investors.insulet.com under the Investor Relations section. Materials accompanying the presentation will also be posted within this section under "Events and Presentations" following the event.
Presentations will be given by the following members of management:
- Patrick Sullivan, Chairman and Chief Executive Officer
- Shacey Petrovic, President and Chief Operating Officer
- Aiman Abdel-Malek, Senior Vice President, Advanced Technology and Engineering
- Charles Alpuche, Senior Vice President, Global Manufacturing and Operations
- Michael Levitz, Senior Vice President and Chief Financial Officer
In addition, the Company will hold a panel discussing the Company’s Artificial Pancreas program, featuring members of the management team, including Dr. Trang Ly, Vice President and Medical Director.
For those unable to join the live webcast, a replay will be available following the event and can be accessed at http://investors.insulet.com.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its Omnipod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The Omnipod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and a fully-automated cannula insertion. Insulet's Delivery Systems business also partners with global pharmaceutical and biotechnology companies to tailor the Omnipod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts. For more information, please visit: http://www.myomnipod.com.
Forward-Looking Statements:
This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 29, 2016 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161104005035/en/
